Biocon launches Yesafili biosimilar to Regeneron’s Eylea in US

PUBT · 2d ago
Biocon launches Yesafili biosimilar to Regeneron’s Eylea in US
  • Biocon Biologics launched Yesafili in the U.S., targeting a high-volume retinal disease market with an interchangeable biosimilar to Eylea 2 mg.
  • Interchangeability supports pharmacy-level substitution under state laws, strengthening pricing leverage with payers and accelerating uptake versus non-interchangeable rivals.
  • Launch positions the group to compete for share in a U.S. aflibercept market that generated about $5.89 billion of sales in 2023.
  • Move expands Biocon’s ophthalmology footprint, adding a new growth driver to its global biosimilars portfolio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: W25PRKAKU13RNO4D) on August 03, 2026, and is solely responsible for the information contained therein.